Brought to you by 
Lin BioScience signs third deal in three months, now with Univ. of Sydney for brain cancer
22 Mar 2017
Executive Summary
The University of Sydney granted Lin BioScience Inc. exclusive global rights to develop and sell a microtubule inhibitor for brain cancer. Lin has named the candidate LBS002.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lin BioScience signs third deal in three months, now with Univ. of Sydney for brain cancer
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice